-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, September 2 News On August 30, Shandong New Times Pharmaceutical submitted an application for the imitation of Temozolomide Capsules 4 types
.
According to data from Meinenet, the sales of terminal temozolomide capsules in China's public medical institutions in 2020 have exceeded 2.
5 billion yuan.
The current domestic market pattern is "original research + 3 domestic production"
.
Figure 1: Product status newly declared by Shandong New Times Pharmaceutical Source: CDE official website Temozolomide is an alkylating agent with anti-tumor activity of imidazotetrazine, which can kill cancer cells by destroying DNA.
Compared with conventional chemotherapy, With the enhancement of efficacy and reduction of side effects, temozolomide capsules have been used as the first-line drug for newly diagnosed and recurrent gliomas
.
Figure 2: for sales of temozolomide capsules (unit: million) Source: network terminal competition pattern of China's public medical institutions on the domestic market in addition to the original research and pharmaceutical companies Merck approved imports, the Tasly, Beijing SL Pharmaceutical is also a major competition in the meter business
.
In 2020, the sales of temozolomide capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China Public Medical Institution Terminal) have exceeded 2.
5 billion yuan, with Tasly and Merck each accounting for more than 40% of the market.
In June 2021, the 4 types of imitations of Tojo Pharmaceuticals were approved for listing and deemed to have been reviewed
.
Temozolomide capsules were included in the fourth batch of national sources.
Tasly and Beijing Shuanglu Pharmaceutical won the bid, which is expected to further grab Merck’s market share
.
Table 1: Situation of new products approved for listing by Shandong New Times Pharmaceutical from 2021 Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Table 2: Situation of products declared and under review by Shandong New Times Pharmaceutical from 2021 Source: Meinenet MED2.
0 China Drug Evaluation Database 2021 is a bumper year for Shandong New Era Pharmaceuticals.
From January to August, a total of 6 high-end chemical drugs and 1 new biological drug were approved for marketing, and axitinib tablets were the first in China.
For imitation, epirubicin hydrochloride injection was the first one to have reviewed.
Rivaroxaban tablets won the fifth batch of national procurement as soon as it was approved.
This year, the company also submitted 3 antimicrobials.
Generic marketing application for tumors and immunomodulators
.
Source: CDE official website, Mi Nei.
com data.
The review data statistics are as of August 31.
If there are any errors or omissions, please correct me
.
.
According to data from Meinenet, the sales of terminal temozolomide capsules in China's public medical institutions in 2020 have exceeded 2.
5 billion yuan.
The current domestic market pattern is "original research + 3 domestic production"
.
Figure 1: Product status newly declared by Shandong New Times Pharmaceutical Source: CDE official website Temozolomide is an alkylating agent with anti-tumor activity of imidazotetrazine, which can kill cancer cells by destroying DNA.
Compared with conventional chemotherapy, With the enhancement of efficacy and reduction of side effects, temozolomide capsules have been used as the first-line drug for newly diagnosed and recurrent gliomas
.
Figure 2: for sales of temozolomide capsules (unit: million) Source: network terminal competition pattern of China's public medical institutions on the domestic market in addition to the original research and pharmaceutical companies Merck approved imports, the Tasly, Beijing SL Pharmaceutical is also a major competition in the meter business
.
In 2020, the sales of temozolomide capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China Public Medical Institution Terminal) have exceeded 2.
5 billion yuan, with Tasly and Merck each accounting for more than 40% of the market.
In June 2021, the 4 types of imitations of Tojo Pharmaceuticals were approved for listing and deemed to have been reviewed
.
Temozolomide capsules were included in the fourth batch of national sources.
Tasly and Beijing Shuanglu Pharmaceutical won the bid, which is expected to further grab Merck’s market share
.
Table 1: Situation of new products approved for listing by Shandong New Times Pharmaceutical from 2021 Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Table 2: Situation of products declared and under review by Shandong New Times Pharmaceutical from 2021 Source: Meinenet MED2.
0 China Drug Evaluation Database 2021 is a bumper year for Shandong New Era Pharmaceuticals.
From January to August, a total of 6 high-end chemical drugs and 1 new biological drug were approved for marketing, and axitinib tablets were the first in China.
For imitation, epirubicin hydrochloride injection was the first one to have reviewed.
Rivaroxaban tablets won the fifth batch of national procurement as soon as it was approved.
This year, the company also submitted 3 antimicrobials.
Generic marketing application for tumors and immunomodulators
.
Source: CDE official website, Mi Nei.
com data.
The review data statistics are as of August 31.
If there are any errors or omissions, please correct me
.
